Bimatoprost
From Wikipedia, the free encyclopedia
 |
|
|
Bimatoprost
|
|
| Systematic (IUPAC) name | |
| 7-[3,5-dihydroxy-2- (3-hydroxy-5-phenyl-pent-1-enyl)- cyclopentyl]-N-ethyl-hept-5-enamide | |
| Identifiers | |
| CAS number | |
| ATC code | S01 |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | C25H37NO4 |
| Mol. mass | 415.566 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | Topical (eye drops) |
Bimatoprost ophthalmic solution is a topical medication used for controlling the progression of glaucoma or ocular hypertension, by reducing intraocular pressure. It is a prostaglandin analogue that works by increasing the outflow of aqueous fluid from the eyes.[1] It is known by the brand name of Lumigan in USA, manufactured by Allergan Inc. Bimatoprost ophthalmic solution 0.03% is a synthetic prostamide analog with ocular hypotensive activity. Its chemical name is (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[1E,3S) -3-hydroxy-5-phenyl-1-pentenyl]cyclopentyl]- 5-N-ethylheptenamide, and its molecular weight is 415.58. Its molecular formula is C25H37NO4.[2]
[edit] Side effects
Possible side effects of this medication are:
- May cause blurred vision;
- May cause eyelid redness;
- May permanently darken eyelashes;
- May cause eye discomfort;
- May eventually cause permanent darkening of the iris to brown (heterochromia).
- May cause a temporary burning sensation during use.
- May cause thickening of the eyelashes.
[edit] References
- Chen M, Cheng C, Chen Y, Chou C, Hsu W (2006). "Effects of bimatoprost 0.03% on ocular hemodynamics in normal tension glaucoma.". J Ocul Pharmacol Ther 22 (3): 188-93. PMID 16808680.
- Kruse P, Rieck P, Sherif Z, Liekfeld A (2006). "Cystoid macular edema in a pseudophakic patient after several glaucoma procedures. Is local therapy with bimatoprost the reason?". Klin Monatsbl Augenheilkd 223 (6): 534-7. PMID 16804825.
- Steinhäuser S (2006). "Decreased high-density lipoprotein serum levels associated with topical bimatoprost therapy.". Optometry 77 (4): 177-9. PMID 16567279.
[edit] External links
|
|
|
|---|---|
| Sympathomimetics | Apraclonidine, Brimonidine, Clonidine, Dipivefrine, Epinephrine |
| Parasympathomimetics | Aceclidine, Acetylcholine, Carbachol, Demecarium, Echothiophate, Fluostigmine, Neostigmine, Paraoxon, Physostigmine, Pilocarpine |
| Carbonic anhydrase inhibitors | Acetazolamide, Brinzolamide, Diclofenamide, Dorzolamide, Methazolamide |
| Beta blocking agents | Befunolol, Betaxolol, Carteolol, Levobunolol, Metipranolol, Timolol |
| Prostaglandin analogues | Bimatoprost, Latanoprost, Travoprost, Unoprostone |
| Other agents | Dapiprazole, Guanethidine |
Alprostadil - Dinoprostone - Prostacyclin
Prostaglandin analogues: Beraprost - Bimatoprost - Carboprost - Enprostil - Iloprost - Latanoprost - Misoprostol - Travoprost - Treprostinil
 |
This article about an ester is a stub. You can help Wikipedia by expanding it. |
